CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Authors
Abou-Alfa GK
Andrew X Zhu
+21Â more
Arndt Vogel
Cheng A
Desai J
Deva S
Feng Y
Frederic Boisserie
Gianluca Tomasello
James Song
Jeannie Hou
Luo L
Masatoshi Kudo
Michel Ducreux
Richard S Finn
Shen L
Shukui Qin
Teresa Mercade Macarulla
Tim Meyer
Xin Li
Yen C
Zhang T
Zhu AX
Publication date
Publisher
'Future Medicine Ltd'
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 28/10/2020